Venous thrombotic events associated with implanted vascular access devices in oncology patients: a prospective cohort study

Author(s):  
Sheryl McDiarmid
2020 ◽  
Vol 122 (6) ◽  
pp. 1027-1030 ◽  
Author(s):  
Jonathan D. Stevenson ◽  
Scott Evans ◽  
Guy Morris ◽  
Roger Tillman ◽  
Adesegun Abudu ◽  
...  

2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Linda L. Coventry ◽  
Jon M. Hosking ◽  
Doris T. Chan ◽  
Evelyn Coral ◽  
Wai H. Lim ◽  
...  

2020 ◽  
Vol 21 (5) ◽  
pp. 746-752
Author(s):  
Aiza Waheed ◽  
Agnes Masengu ◽  
Tomas Skala ◽  
Guiyun Li ◽  
Jacek Jastrzebski ◽  
...  

Background: A substantial proportion of arteriovenous fistulas fail to function adequately for hemodialysis. Existing studies on arteriovenous fistula failure prediction assess patency rather than the more clinically relevant outcome of arteriovenous fistula function. We hypothesized that preoperative demographic and ultrasound characteristics, and postoperative assessment by an experienced vascular access nurse would predict which arteriovenous fistulas will not function adequately for hemodialysis. Methods: Prospective cohort study of chronic kidney disease patients at a tertiary care center in Vancouver, Canada, with arteriovenous fistula creation between 2009 and 2013. Pre and postoperative clinical assessment and ultrasound blood vessel mapping were performed by an experienced vascular access nurse. The primary outcome was failure to achieve a fistula used successfully for hemodialysis (FUSH). Results: Outcomes were assessed in 200 patients; 123 (61.5%) arteriovenous fistulas were radiocephalic. Overall, 26.5% of arteriovenous fistulas had FUSH failure (34.1% of lower arm vs 14.3% of upper arm, p = 0.002). Univariate predictors of FUSH failure included older age (p = 0.03), female sex (p = 0.05), smaller arterial diameter (p ⩽ 0.001), lower artery volume flow (p = 0.04), and smaller vein diameter (p = 0.01). In multivariable analysis, artery diameter (odds ratio: 0.44, 95% confidence interval: 0.28–0.68) most significantly predicted FUSH failure. Vascular access nurse assessment 6 weeks postoperatively correctly predicted outcome in 83.8% of FUSH and 65.0% of FUSH failure. Conclusion: Smaller artery diameter most strongly predicted FUSH failure. Early postoperative nursing assessment was more useful to predict FUSH than FUSH failure, and as such was insufficient in determining which arteriovenous fistulas should be abandoned as many predicted to fail could be salvaged with further intervention.


2018 ◽  
Vol 7 (5) ◽  
pp. e136 ◽  
Author(s):  
Michael Marthick ◽  
Haryana M Dhillon ◽  
Jennifer A Alison ◽  
Birinder S Cheema ◽  
Tim Shaw

Vaccines ◽  
2021 ◽  
Vol 10 (1) ◽  
pp. 12
Author(s):  
Innocenza Palaia ◽  
Giuseppe Caruso ◽  
Violante Di Donato ◽  
Annarita Vestri ◽  
Anna Napoli ◽  
...  

Objective: To evaluate the safety and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine in gynecologic oncology patients under chemotherapy. Methods: A prospective cohort study including gynecologic oncology women who were under chemotherapy or had completed it within 6 months at the time of the study. All patients received a two-dose schedule of the Pfizer-BioNTech COVID-19 vaccine. Results were compared with a control group of healthy women vaccinated in the same period. Results: Overall, 44 oncologic patients with a mean age of 61.3 ± 10.7 years were enrolled: 28 (63.6%) had ovarian cancer, 9 (20.4%) endometrial, and 7 (16%) cervical. The IgG antibody titer after 1 month from vaccination was low in 9 (20.5%) patients, moderate in 21 (47.7%), and high in 14 (31.8%). The 3-month titer was null in 2 (4.5%) patients, low in 26 (59.1%), moderate in 13 (29.5%), and high in 3 (6.8%). Patients ≥ 50 years reported lower 1-month (p = 0.018) and 3-month (p = 0.004) titers compared with <50 years. Patients with BMI < 30 kg/m2 had a higher 1-month titer compared with BMI ≥ 30 kg/m2 (p = 0.016). Compared with healthy women (n = 44), oncologic patients showed a lower 3-month titer (p < 0.001). None of the patients experienced serious adverse effects. Conclusions: The COVID-19 vaccine was safe and immunogenic in gynecologic oncology patients under chemotherapy. Serological monitoring and further vaccine shots should be considered to boost protection.


Author(s):  
Mika Kivimaki ◽  
Marko Elovainio ◽  
Jussi Vahtera ◽  
Marianna Virtanen ◽  
Jane E. Ferrie

Sign in / Sign up

Export Citation Format

Share Document